基于流行病学的死亡率评分与癫痫持续状态后长期死亡率相关
本研究为回顾性队列研究,纳入2008年1月至2014年12月间成人首次非缺氧性癫痫持续状态患者129例,中位随访24.8个月。比较STESS与EMSE-EACE对院内死亡、3个月死亡及长期死亡的预测能力,发现两评分对院内和3个月死亡预测无显著差异。至研究结束时,EMSE-EACE≥64与总生存关联最佳:该组仅15.7%(8/51)存活,而STESS≥3组为32.4%(24/74);EMSE-EACE≥64组中位生存6.4个月(95%CI 2.3-15.3),<64组为35.8个月(95%CI 32.8-37.9)。在存活出院患者中,EMSE-EACE与出院后死亡高度显著相关(p<0.001)。
要点
- EMSE-EACE≥64的癫痫持续状态患者长期生存差:中位生存6.4个月(95%CI 2.3-15.3),而<64组为35.8个月(95%CI 32.8-37.9)。
- 至研究结束时,EMSE-EACE≥64组仅15.7%(8/51)存活,STESS≥3组为32.4%(24/74)。
- 在存活出院患者中,EMSE-EACE与出院后死亡高度显著相关(p<0.001),STESS≥3仅边缘显著(p=0.04),STESS≥4未达统计学显著(p=0.23)。
- STESS与EMSE-EACE在预测院内死亡和3个月死亡方面无显著差异。
- 探索性分析显示,病因与院内死亡强相关,但与长期生存无关;在存活出院患者中,仅合并症和年龄仍与长期死亡显著相关。
适用人群与场景
- 成人首次非缺氧性癫痫持续状态患者,发病时间2008年1月至2014年12月。
诊断标准与关键阈值
- EMSE-EACE评分≥64为与总生存关联最佳的界值。
- STESS评分≥3和STESS≥4为研究分析的界值。
研究设计与关键结果
- 回顾性队列研究,纳入129例成人首次非缺氧性癫痫持续状态患者,中位随访24.8个月。
- STESS与EMSE-EACE在预测院内死亡和3个月死亡方面无显著差异。
- 至研究结束时,EMSE-EACE≥64组存活15.7%(8/51),STESS≥3组存活32.4%(24/74)。
- EMSE-EACE≥64组中位生存6.4个月(95%CI 2.3-15.3),EMSE-EACE<64组为35.8个月(95%CI 32.8-37.9)。
- 存活出院患者中,EMSE-EACE与出院后死亡高度显著相关(p<0.001);STESS≥3仅边缘显著(p=0.04),STESS≥4未达统计学显著(p=0.23)。
- 探索性分析:病因与院内死亡强相关,但与长期生存无关;存活出院患者中仅合并症和年龄与长期死亡显著相关。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,EMSE-EACE与出院后长期生存显著相关,可用于癫痫持续状态患者出院后的预后分层。
- 在存活出院患者中,EMSE-EACE与长期死亡的关联强于STESS,STESS≥4未达统计学显著。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Status epilepticus (SE) is a life-threatening condition with a high long-term mortality. The correct prediction of the individual patient's outcome is crucial for stratifying treatment. Status epilepticus severity score (STESS) and the epidemiology-based mortality score (EMSE) are well established for predicting in-hospital mortality; however, scores indicating long-term mortality are lacking. We here studied the association of both scores with mortality after discharge and long-term mortality.
METHODS: In this retrospective cohort study of adult patients with incident, non-anoxic, first-time SE (from 01/2008 to 12/2014), STESS, EMSE-EACE (etiology-age-comorbidity-EEG), demographic data, modified Rankin Scale at discharge, treatment, date of diagnosis, and date of death were determined based on electronic patients charts.
RESULTS: A total of 129 patients with a median follow-up of 24.8 months were included. We found no significant difference between STESS and EMSE-EACE in predicting in-hospital and 3 months mortality. At end-of-study, EMSE-EACE with a cutoff of ≥ 64 showed the best association with overall survival. At last follow-up, only 15.7% (8 out of 51) of the patients with EMSE ≥ 64 were alive as compared to 32.4% (24 out of 74) of the patients with STESS ≥ 3. Median survival of patients with EMSE-EACE ≥ 64 and EMSE-EACE < 64 was 6.4 months (95% confidence interval (CI) 2.3-15.3 months) and 35.8 months (CI 32.8-37.9 months), respectively. In the subgroup of patients that were discharged alive from the hospital, EMSE-EACE was highly significantly associated with mortality (p < 0.001) after discharge. In the same patients, STESS with a cutoff of STESS ≥ 3 reached only borderline significance (p = 0.04), STESS with a cutoff of STESS ≥ 4 did not reach statistical significance (p = 0.23). Exploratory analyses of different EMSE components unveiled a strong association of etiology with in-house mortality but not with long-term survival. In patients discharged alive from the hospital, only comorbidity and age remained significantly associated with long-term mortality.
CONCLUSIONS: In our cohort, EMSE-EACE was significantly associated with long-term survival after discharge.
参考来源
- Møller HS, Rodin E, Aukland P, et al. Epidemiology-Based Mortality Score is Associated with Long-Term Mortality after Status Epilepticus. Neurocrit Care. 2019. PMID: 30607827. doi:10.1007/s12028-018-0663-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。